Better Nuclear Energy Stock to Buy After the Sell-Off: Oklo vs. X-Energy

Oklo and X-Energy remain pre-commercial, loss-making nuclear reactor developers, but their deployment timelines and valuations differ sharply. Analysts expect Oklo revenue to increase from less than $3 million in 2026 to $51 million in 2028, while losses widen from $161 million to $210 million; it trades at 100 times 2028 sales. X-Energy is not expected to deploy SMRs until the early 2030s, but analysts forecast revenue rising from $212 million in 2026 to $1.2 billion in 2028 and losses narrowing from $430 million to $125 million; it trades at 2.5 times 2028 sales. The article favors X-Energy as the relatively undervalued choice, while noting execution and capital-intensity risks.

Analysis

The key mispricing risk is treating announced pipeline and forecast revenue as equivalent to bankable reactor economics. Oklo’s earlier target date is valuable only if licensing, fuel qualification, construction and customer conversion occur on schedule; slippage would defer a high-multiple revenue ramp while losses continue. X-Energy’s lower sales multiple is not automatically cheap: the cited 2026–28 revenue appears largely pre-commercial, so it does not validate reactor-level margins, and first deployment is much farther out. Its proprietary TRISO fuel adds a potential bottleneck and capital burden, but successful fuel qualification could become a moat. For both, customer announcements may be conditional rather than firm offtake; verify contract terms and project financing. In particular, the stated 500 GW Equinix agreement is anomalous relative to the other figures and should be checked for a unit or scope error before using Oklo’s backlog. Near term, volatility and execution headlines likely dominate. Over 1–3 months, watch regulatory milestones, firm contract disclosures, funding/dilution and revised deployment schedules. Over 6–18 months, fuel and licensing progress matter more than headline pipeline. Contrarian point: XE’s apparent valuation discount may reflect a genuine decade-long commercialization gap, while OKLO’s premium may be partly justified by earlier potential revenue—but neither valuation is anchored by operating reactor results.

Key Decisions for Investors

• Avoid an unhedged long in either name on pipeline figures alone. Treat analyst revenue estimates as scenarios, not verified guidance; require evidence of binding offtake, project financing and licensing progress before sizing a long.
• If seeking relative exposure, consider a small, risk-defined long XE / short OKLO pair rather than a standalone XE position, with the thesis limited to relative valuation and contingent on XE maintaining funding and fuel milestones. Reassess if XE’s pre-commercial revenue outlook weakens or OKLO demonstrates financed, on-schedule deployment.
• For OKLO, make any entry contingent on confirmation of the Equinix agreement’s unit and scope, plus credible licensing and construction milestones for the first commercial units. A delayed schedule, worsening losses or material equity issuance would falsify the near-term premium thesis.
• For XE, monitor TRISO qualification and manufacturing capacity, cash burn/funding needs, and whether the projected engineering and grant revenue converts to cash. Failure on fuel or financing, or a further slip beyond the early-2030s deployment window, would undermine the discount case.